
BioNTech and Beyond
07/27/23 • 38 min
After the success of previously unknown biopharma company BioNTech in combatting Covid, Germany is back in the spotlight as “the world’s pharmacy.” But what comes next for the sector? And how can international health-sector companies profit? We talk to the world’s oldest pharmaceutical company Merck, a serial entrepreneur and a biotech journalist about personal medication, international partnerships and mRNA technology and its potential for fighting cancer.
Our guests
Laura Matz is the Chief Science and Technology Officer for Merck, Darmstadt, Germany. An executive vice-president, she’s responsible for the corporate innovation teams including the digital office and new digital business models. She has 20 years of experience in semiconductor manufacturing and a decade of experience running semiconductor materials businesses. She has a PhD in analytical chemistry from Washington State University.
Maike Becker-Krüger studied International Relations at Lake Forest College in Chicago and at Franklin University in Switzerland. This was followed by an MBA from Quadriga University Berlin. She worked directly for state premier of the regional German state of Hessen before taking responsibility for European policy coordination within the national government. Starting in 2015, she has built up the capital city office and the Corporate and Government Relations Berlin department at Merck. Since 2022, Maike Becker-Krüger has been Head of EU & Germany Corporate Affairs.
Oliver Schacht is a corporate finance professional and expert in the molecular diagnostics industry and CEO of OpGen. He has co-founded several start-up companies in biotech, clean tech, IT and education in Europe and the US and has experience in developing and implementing commercial strategies and financing measures (including two IPOs). He also serves as the chairman of the Board of Internal Council of Biotechnology Assocations and the president of the German industry association BIO Deutschland. He studied European Business Administration in Reutlingen and London and holds a PhD from Cambridge University (UK).
Dr. Georg Kääb studied biology in Regensburg and Munich and earned his doctorate in neuroimmunology. After freelancing for the Süddeutsche Zeitung newspaper, he became editor-in-chief and co-managing director at the Association of German Biologists. From 2007 to 2021, he headed the communication of the cluster organization BioM (Martinsried), was managing director of the Biotechnology Cluster Bavaria and spokesperson for BioRegions in Germany. Since autumn 2021, he has headed the editorial team of the biotechnology magazine division at media company BIOCOM AG.
Send your feedback and comments to [email protected].
After the success of previously unknown biopharma company BioNTech in combatting Covid, Germany is back in the spotlight as “the world’s pharmacy.” But what comes next for the sector? And how can international health-sector companies profit? We talk to the world’s oldest pharmaceutical company Merck, a serial entrepreneur and a biotech journalist about personal medication, international partnerships and mRNA technology and its potential for fighting cancer.
Our guests
Laura Matz is the Chief Science and Technology Officer for Merck, Darmstadt, Germany. An executive vice-president, she’s responsible for the corporate innovation teams including the digital office and new digital business models. She has 20 years of experience in semiconductor manufacturing and a decade of experience running semiconductor materials businesses. She has a PhD in analytical chemistry from Washington State University.
Maike Becker-Krüger studied International Relations at Lake Forest College in Chicago and at Franklin University in Switzerland. This was followed by an MBA from Quadriga University Berlin. She worked directly for state premier of the regional German state of Hessen before taking responsibility for European policy coordination within the national government. Starting in 2015, she has built up the capital city office and the Corporate and Government Relations Berlin department at Merck. Since 2022, Maike Becker-Krüger has been Head of EU & Germany Corporate Affairs.
Oliver Schacht is a corporate finance professional and expert in the molecular diagnostics industry and CEO of OpGen. He has co-founded several start-up companies in biotech, clean tech, IT and education in Europe and the US and has experience in developing and implementing commercial strategies and financing measures (including two IPOs). He also serves as the chairman of the Board of Internal Council of Biotechnology Assocations and the president of the German industry association BIO Deutschland. He studied European Business Administration in Reutlingen and London and holds a PhD from Cambridge University (UK).
Dr. Georg Kääb studied biology in Regensburg and Munich and earned his doctorate in neuroimmunology. After freelancing for the Süddeutsche Zeitung newspaper, he became editor-in-chief and co-managing director at the Association of German Biologists. From 2007 to 2021, he headed the communication of the cluster organization BioM (Martinsried), was managing director of the Biotechnology Cluster Bavaria and spokesperson for BioRegions in Germany. Since autumn 2021, he has headed the editorial team of the biotechnology magazine division at media company BIOCOM AG.
Send your feedback and comments to [email protected].
Previous Episode

Gaming in Germany
Playing to Win in a Major Business Growth Sector
Think Germany, and you probably don’t think fun and games. But you should. Where else is gaming a special part of the Economics Ministry? Germans are absolutely fanatics for games and represent Europe’s biggest electronic gaming market, with some 49 million active players. To get the latest on this dynamic sector, we talk to one of Europe’s leading games developers and the head of the German Association for the Games Industry.
Our guests Benedikt Grindel is managing director of Ubisoft Blue Byte and also heads Ubisoft Düsseldorf. Grindel studied mathematics with a minor in business administration at the University of Münster. He joined Ubisoft in 1998 and worked for three years in the marketing and business development department. He then moved to the game development studio Blue Byte after it was acquired by Ubisoft. As a producer, he was responsible for the "The Settlers" brand, and in 2010 he launched the live operation unit at Ubisoft Blue Byte. In 2014, he took on the role of managing director. Felix Falk has been managing director of game since February 1, 2018. From 2009 to 2016, he was managing director of the Entertainment Software Self-Regulation Body (USK). As vice chairman of the International Age Rating Coalition (IARC), he helped develop the global labeling standard for online games and apps during this time. From 2004 to 2009, he headed the office of Monika Griefahn, chair of the Committee for Culture and Media in the German Bundestag. In this capacity, he was responsible for the computer games and, among other things, helped create the the German Computer Game Prize, which was awarded for the first time in 2009. Send your feedback and comments to [email protected].
Next Episode

The Race to Net Zero
Germany’s Second Solar Power Business Boom
The stakes could not be higher. Germany aspires to lead the way in achieving carbon emissions neutrality. To that, it’s going to need lots and lots of regenerative energy, including solar power. The country already experienced a solar boom around the turn of millennium, but it didn’t last. Now, the sun is back at the center of Germany’s transition to clean energy and its new energy economy. Can solar succeed this time around in Europe’s largest market? We get assessments from a CTO of an up-and-coming solar company and a sector expert.
Our guests
Chris Case is the CTO of Oxford PV, a solar energy company that has expanded to the eastern German city of Brandenburg, He’s a board member of the European Solar Manufacturing Council, a steering committee member of the European Technology and Innovation Platform for Photovoltaics (ETIP-PV) and, since 2021, the president of the International Thin-Film Solar Industry Association (PVthin). He also advises the SuperSolar Hub of the UK Engineering and Physical Sciences Research Council (ESPRC). He has extensively published in international newspapers and scientific journals and is a regular speaker and lecturer on integrated circuits and photovoltaics.
David Wedepohl is a trained radio journalist who studied and has worked on both sides of the Atlantic. He first came in contact with the solar industry while working for an American consulting company, which he left to take up a job as director of communications and markets at the German Solar Association. He also served as the association's spokesperson. He is now that organization’s managing director of international affairs, working on projects in North, West and Southern Africa, Latin America, Southeast Asia and the US.
Send your feedback and comments to [email protected].
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/into-germany-the-german-business-podcast-643003/biontech-and-beyond-85226005"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to biontech and beyond on goodpods" style="width: 225px" /> </a>
Copy